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Objectives. This study was designed to examine whether short-
term estrogen administration ameliorates dobutamine-induced
myocardial ischemia in postmenopausal women with coronary
artery disease (CAD).
Background. Estrogen replacement therapy in postmenopausal
women is associated with a marked reduction in the risk of CAD.
Estrogen has been reported to have both short- and long-term
effects on the cardiovascular system. However, it remains to be
examined whether short-term estrogen administration amelio-
rates myocardial ischemia caused by increased myocardial oxygen
demand in postmenopausal women with CAD.
Methods. Eight postmenopausal women with proved CAD
underwent dobutamine stress echocardiography (DSE). DSE was
performed three times in a placebo-controlled, double-blind man-
ner: 1) 30 min after intravenous administration of saline solution
(placebo) and after 2) a low dose (1.25 mg) and 3) a high dose
(10 mg) of conjugated estrogen. The effects of estrogen were
compared at the maximal comparable stage of DSE, which was the
maximal DSE level that the same patient achieved in all three
examinations.
Results. Estrogen dose-dependently ameliorated the dobutamine-
induced worsening of symptoms (prolonging time to onset of
symptoms by 52% [low dose] and 72% [high dose]), electrocar-
diographic findings (decreasing the magnitude of summed ST
segment changes by 36% [low dose] and 76% [high dose]) and left
ventricular wall motion (reducing the wall motion score index by
50% [low dose] and 77% [high dose], all p < 0.01 by analysis of
variance). There was no significant difference in blood pressure,
heart rate or rate-pressure product among the three examinations
at the maximal comparable stage of DSE.
Conclusions. Estrogen has short-term anti-ischemic effects on
the myocardial ischemia induced by increased myocardial oxygen
demand in postmenopausal women with CAD.
(J Am Coll Cardiol 1997;30:1466–71)
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Epidemiologic studies have shown that estrogen replacement
therapy achieves an ;50% reduction in the risk of coronary
heart disease among postmenopausal women (1). Estrogen
replacement therapy has more beneficial effects in reducing
the incidence of cardiovascular events in postmenopausal
women with coronary artery disease (CAD) than in those
without CAD. Sullivan et al. (2) reported that estrogen re-
placement therapy in postmenopausal women with CAD re-
duced the mortality rate at 10 years from 35% to 14%.
Beneficial effects of estrogen are not totally attributable to
their favorable effects on plasma lipid levels (3). Another
possible mechanism for the beneficial effects of estrogen is its
vascular effects, including endothelium-dependent relaxation
(4–6), endothelium-independent and calcium antagonistic va-
sodilating effect (7–9) and antioxidant effect (10). It has
recently been reported (11) that sublingual administration of
17-beta-estradiol has short-term beneficial effects on myocar-
dial ischemia during treadmill exercise testing in postmeno-
pausal women with CAD. However, exercise tolerance during
treadmill testing may be determined both by cardiac factors
(e.g., mechanical function of the heart) and by noncardiac
factors (e.g., pulmonary function and peripheral arterial dis-
ease). Thus, this beneficial effect of estrogen may in part be
due to the noncardiac effects of the hormone. To our knowl-
edge, the short-term effects of estrogen administration on left
ventricular (LV) wall motion during myocardial ischemia have
not been directly investigated.
This study was thus designed to examine whether short-
term estrogen administration ameliorates the myocardial isch-
emia during dobutamine stress echocardiography (DSE) in
postmenopausal women with CAD.
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Methods
Subjects. Eight postmenopausal women with CAD proved
by coronary arteriography were included in this study. The
mean age was 69 years (range 53 to 79). No patient was
receiving estrogen replacement therapy. All patients gave a
written informed consent before the examination. No other
patients were examined in the present study, and thus no
exclusion took place before the examination. Study protocol
was approved by the Human Research Committee at the
Research Institute of Angiocardiology, Kyushu University
School of Medicine. The clinical characteristics of the patients
are shown in Table 1.
DSE. DSE was performed three times in 2 weeks, in a
placebo-controlled, double-blind manner: 1) 30 min after
intravenous bolus administration of saline solution (5 ml) and
after 2) a low dose (1.25 mg) and 3) a high dose (10 mg) of
estrogen diluted in 5 ml of saline solution. The three exami-
nations were performed at the same time of day in the same
patient. Among the medications only beta-adrenergic receptor
blocking agents were discontinued 1 day before the examina-
tion. No patient was receiving verapamil or diltiazem, which
could suppress the heart rate response to dobutamine. The
presence of unstable angina, profound anemia, electrolyte
imbalance or uncontrolled hypertension (systolic blood pres-
sure .190 or diastolic blood pressure .100 mm Hg, or both)
was regarded as a contraindication for DSE.
The patients were in the left lateral decubitus position
throughout the study. They were asked to report the onset of
chest pain or discomfort, or both, during the examination.
Dobutamine was administered intravenously by an infusion
pump. The starting dose of dobutamine was 5 mg/kg per min
and the dose of dobutamine was increased in stepwise manner
to 10, 20, 30, 40 and 50 mg/kg per min every 4 min until one of
the following general end points was reached: target heart rate
(85% of age-predicted maximal heart rate), peak dose, isch-
emic electrocardiographic (ECG) changes (.1 mm ST seg-
ment depression or elevation in more than two leads), severe
hypertension (systolic blood pressure .220 mm Hg or diastolic
blood pressure .110 mm Hg, or both), hypotension
(.20 mm Hg decrease in systolic blood pressure compared
with the rest blood pressure), chest pain or patient refusal to
continue. When the patient experienced only mild chest dis-
comfort or dyspnea without any of the preceding end points,
the dobutamine infusion was continued until an end point was
reached. However, a patient’s report of such chest discomfort
or dyspnea was regarded as the onset of symptoms.
Two-dimensional echocardiograms were obtained at rest,
3 min after dobutamine infusion at each stage and 10 min after
the end of the dobutamine infusion. Atropine was not used in
any patient. Echocardiographic images included parasternal
long-axis, parasternal short-axis, apical two-chamber and api-
cal four-chamber views; they were stored on S-VHS videotapes
(Black Magnetite, Maxell, Tokyo, Japan) for off-line analysis.
Twelve-lead ECGs were recorded at each stage (Auto
Cardiner FCP-4301, Fukuda Denshi, Tokyo, Japan) and the
patient also was continuously monitored by three-lead ECGs
during the examination. Blood pressure was measured at each
stage with a cuff manometer in the right or left arm opposite to
the dobutamine infusion side. Time to onset of symptoms
(chest pain, chest discomfort or dyspnea) was also recorded.
ST segment depression was measured 0.08 s after the J point,
and ST elevation was measured 0.02 s after the J point. The
sum of ST shift was calculated by summing the ST elevations or
depressions in 12-lead ECGs (12).
We have previously confirmed that our DSE examination is
reproducible to detect the presence of CAD. Our DSE exam-
ination has a sensitivity of 79% and a specificity of 92%
(unpublished observations).
Analysis of DSE. Echocardiograms were independently
interpreted in blinded manner by two experienced cardiolo-
gists familiar with the analysis of LV wall motion. LV wall
motion was analyzed in a 16-segment model as suggested by
Abbreviations and Acronyms
ANOVA 5 analysis of variance
CAD 5 coronary artery disease
ECG 5 electrocardiogram, electrocardiographic
DSE 5 dobutamine stress echocardiography
(echocardiographic)
LV 5 left ventricular
Table 1. Clinical Characteristics of the Eight Postmenopausal Women
Patient
No.
Age
(yr)
Coronary Artery
Disease
Old Myocardial
Infarction Risk Factors
1 53 1-VD (LAD) No Hypertension, NIDDM
2 75 3-VD Yes (apical) Hypertension, NIDDM, hyperlipidemia
3 75 Left main trunk No Hypertension, NIDDM, hyperlipidemia
4 58 1-VD (LAD) Yes (anterolateral) Hypertension
5 79 1-VD (LAD) No Hypertension
6 72 2-VD (LAD, RCA) No Hyperlipidemia
7 70 1-VD (RCA) Yes (inferior) Hypertension, NIDDM, hyperlipidemia
8 75 3-VD No Hypertension, hyperlipidemia
LAD 5 left anterior descending coronary artery; NIDDM 5 non–insulin-dependent diabetes mellitus; RCA 5 right
coronary artery; VD 5 vessel disease.
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the American Society of Echocardiography (13). Wall motion
index was scored in the following manner (14): normal 5 1;
hypokinesia, severe hypokinesia or failure of hyperkinesia to
develop 5 2; akinesia 5 3; dyskinesia 5 4; and aneurysmal 5
5. Hyperdynamic wall motion was regarded as the normal
response to dobutamine infusion (14). Wall motion score index
was calculated for every stage of DSE. Scoring was not
performed if a particular segment was not clear enough for
interpretation. The scores were summed and divided by the
number of available segments to obtain the wall motion score
index.
The tolerance to dobutamine varied even in the same
patient among the three examinations. Thus, the changes in
the wall motion score index or the ST segment level from rest
conditions to the maximal comparable stage of DSE, that is the
maximal DSE level that the same patient could achieve in all
three examinations, was determined to examine the effect of
estrogen.
The changes in wall motion score index were determined by
the two cardiologists, and the mean value was used for the
analysis. We confirmed that there was an excellent intraob-
server (r 5 0.95, p , 0.001) and interobserver (r 5 0.96, p ,
0.001) consistency (by a single-variable linear regression anal-
ysis).
Measurements of serum levels of estrogen and lipid perox-
ides. Venous blood was sampled three times during each DSE
examination: before and 30 min after the injection of test
medication (just before starting DSE) and 10 min after the end
of dobutamine infusion. The serum levels of the three estrogen
fractions (estrone, estradiol and estriol) were analyzed by
radioimmunoassay (15). Serum levels of lipid peroxides were
also analyzed by the thiuobarbituric acid method (16).
Drugs. Conjugated estrogen (Premarin, 20 mg/5 ml physi-
ologic saline solution for intravenous use) was purchased from
Asahi Chemicals (Tokyo, Japan) and dobutamine chloride
from Shionogi Co. Ltd. (Osaka, Japan).
Statistical analysis. Results are expressed as the mean
value 6 SEM. Throughout the text, n means the number of
patients. Data obtained from three examinations (saline solu-
tion and a low and a high dose of estrogen) were analyzed by
analysis of variance (ANOVA) for repeated measures; if a
significant F value was found, the Scheffe´ test for multiple
comparisons was used to identify any differences among the
three groups. A p value , 0.05 was considered statistically
significant.
Results
Serum levels of estrogen and lipid peroxides. After injec-
tion of a low dose of estrogen, serum levels of estrone and
estradiol significantly increased to premenopausal levels
whereas those of estriol did not change (Fig. 1). After admin-
istration of a high dose of estrogen, serum levels of estrone and
estradiol further increased to supraphysiologic levels whereas
those of estriol again did not change (Fig. 1). The serum levels
of estrone and estradiol remained increased without a signifi-
cant decrease during the examination period (Fig. 1).
Serum levels of lipid peroxides under control conditions
were within normal ranges (2 to 6 nmol/ml) in all three
examinations: 3.3 6 0.2, 3.5 6 0.2 and 3.5 6 0.2 nmol/ml in the
examinations with saline and low and high dose estrogen,
respectively. These lipid peroxide levels did not change signif-
icantly after administration of either estrogen or dobutamine
(data not shown).
End point of DSE. Among the 24 DSE examinations, the
dobutamine infusion was stopped because of chest pain in 14,
achievement of the peak dose of dobutamine in 6, and ischemic
ST segment changes in 4. Thus, the maximal comparable stage
Figure 1. Time course of serum estrogen levels. Data are expressed as
mean value 6 SEM (n 5 8). Serum levels of estrone and estradiol, but
not those of estriol, increased significantly after intravenous adminis-
tration of both low (solid circles [1.25 mg]) and high dose (open circles
[10 mg]) conjugated estrogen. Serum levels of estrogen remained
increased throughout DSE. Crossmarks 5 saline. *p , 0.01 versus
control.
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of DSE (as expressed by the dobutamine dose, mg/kg per min)
was 10 (n 5 1), 20 (n 5 4), 40 (n 5 2) and 50 (n 5 1). The
patients reported that the dobutamine-induced chest pain was
similar to that experienced in their daily life.
Changes in hemodynamic variables. No significant differ-
ence was noted in heart rate, blood pressure or rate-pressure
product among the three examinations (Table 2). Administra-
tion of estrogen, both low and high dose, did not significantly
change heart rate, blood pressure or rate-pressure product
before and 30 min after estrogen administration. However, at
the maximal comparable stage of DSE, heart rate and rate-
pressure product, but not blood pressure, significantly in-
creased over values in control conditions (Table 2).
Effect of estrogen on symptoms. Estrogen significantly and
dose-dependently prolonged the time to the onset of symptoms
(p , 0.01 by ANOVA) (Fig. 2). The mean value of the percent
prolongation of the time to the onset of symptoms was 52% at
a low dose and 72% at a high dose of the hormone (Fig. 2).
Effects of estrogen on ECG changes. Estrogen significantly
and dose-dependently reduced the magnitude of the summed
ST segment changes (p , 0.01 by ANOVA) (Fig. 3). The mean
value of the percent reduction of the ST segment changes was
36% at a low dose and 76% at a high dose of the hormone (Fig.
3).
Effect of estrogen on wall motion abnormalities. Estrogen
significantly and dose-dependently ameliorated the worsening
of the wall motion score index at the maximal comparable
stage of DSE (p , 0.01 by ANOVA) (Fig. 4). The mean value
of the percent reduction of the wall motion score index was
50% at a low dose and 77% at a high dose of the hormone (Fig.
4).
Influence of baseline wall motion abnormalities. The pre-
ceding beneficial effects of estrogen on dobutamine-induced
symptoms, ECG changes and wall motion abnormalities were
noted in our postmenopausal patients with CAD, regardless of
the presence or absence of baseline wall motion abnormalities
(data not shown).
Discussion
The novel finding of the present study is that short-term
administration of conjugated estrogen significantly amelio-
rated the dobutamine-induced myocardial ischemia in post-
menopausal women with CAD.
DSE. Dobutamine is a synthetic catecholamine and has
effects on beta1-, beta2- and alpha1-adrenergic receptors
(17,18). Dobutamine increases myocardial oxygen demand by
increasing heart rate and myocardial contractility (17,18)
mainly due to beta1-adrenergic receptor stimulation. The
Table 2. Hemodynamic Variables
Control Before DSE
At a Maximal
Comparable Stage
Saline solution
HR 62 6 3 58 6 3 95 6 6*
Systolic BP 136 6 6 137 6 6 149 6 6
Diastolic BP 72 6 4 73 6 4 71 6 4
RPP (3103) 8,525 6 634 8,090 6 511 14,223 6 1,118*
Estrogen
Low dose
HR 60 6 3 58 6 3 99 6 6*
Systolic BP 134 6 5 135 6 3 139 6 7
Diastolic BP 68 6 3 66 6 3 67 6 4
RPP (3103) 8,187 6 586 7,961 6 442 13,962 6 1,358*
High dose
HR 58 6 3 56 6 2 92 6 4*
Systolic BP 143 6 3 138 6 4 142 6 6
Diastolic BP 77 6 6 72 6 6 67 6 6
RPP (3103) 8,252 6 486 7,711 6 302 13,280 6 1,017*
*p , 0.01 versus control. Data are expressed as mean value 6 SEM (n 5 8).
BP 5 blood pressure (mm Hg); DSE 5 dobutamine stress echocardiography;
HR 5 heart rate (beats/min); RPP 5 rate-pressure product calculated as heart
rate 3 systolic blood pressure.
Figure 2. Time (min) to onset of symptoms. Data are presented as
mean value 6 SEM (n 5 8). The time to onset of symptoms of 24 min
indicates that the patient completed the DSE examination without
chest pain. Estrogen (E) dose-dependently prolonged the onset of
symptoms during DSE (p , 0.01 by ANOVA).
Figure 3. Summed ST segment changes (mm) from control to the
maximal comparable stages of DSE. Data are presented as mean
value 6 SEM (n 5 8). Estrogen (E) dose-dependently decreased the
magnitude of summed ST segment changes from control levels to
maximal comparable stages of DSE (p , 0.01 by ANOVA).
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beta2- and alpha1-adrenergic agonist activities of dobutamine
are relatively milder than its beta1-adrenergic activity. Because
beta2- and alpha1-adrenergic effects of dobutamine are bal-
anced in peripheral vasculature, dobutamine infusion, espe-
cially at low doses, has minimal effects on blood pressure (17).
In the presence of CAD, the increased myocardial oxygen
demand by dobutamine is associated with an inadequate
increase in coronary blood flow, resulting in myocardial isch-
emia and abnormal LV wall motion that can be detected by
cross-sectional echocardiography (14).
DSE has several advantages over exercise echocardiogra-
phy (19). First, myocardial ischemia can be easily induced by
dobutamine infusion in almost all patients, whereas exercise
echocardiography cannot always be performed in all patients.
Second, because DSE allows echocardiographic imaging at
every stage of dobutamine infusion, we were able to analyze
LV wall motion at the maximal comparable stage of DSE in
our study, whereas exercise echocardiography can be per-
formed only after exercise.
In the present study, heart rate responses were slightly
lower than those in previous reports (17,18). We consider that
this difference occurred in part because only two of our
patients could achieve a dobutamine infusion rate of 50 mg/kg
per min in four DSE examinations, and in part because the
relatively older age of our patients (mean 69 years) may have
blunted the heart rate response to the dobutamine stimulation.
However, because rate-pressure products were comparable
among the three examinations in our study, we were able to
examine the effects of estrogen at the maximal comparable
level of myocardial oxygen demand.
Anti-ischemic effect of estrogen. In the present study, we
observed the short-term anti-ischemic effects of estrogen,
which may be attributed to the following vascular effects of this
hormone:
1. Estrogen may ameliorate the extent of myocardial isch-
emia by enhancing the endothelium-dependent vasodilation of
the coronary artery. Previous studies have demonstrated that
an increase in sympathetic tone, such as that caused by mental
stress (20), exercise (21) or cold pressor test (22), causes
dilation of normal coronary arteries and paradoxic constriction
of atherosclerotic coronary arteries with dysfunctional endo-
thelium. Thus, enhanced endothelium-dependent relaxation
may play a protective role to delay or prevent the occurrence
of myocardial ischemia in patients with CAD. Physiologic
levels of 17-beta-estradiol were shown (23) to immediately and
selectively potentiate endothelium-dependent dilation in both
large coronary arteries and coronary microvessels in post-
menopausal women. We (24) also recently demonstrated that
estrogen immediately improves both nitric oxide–mediated
and non-nitric oxide (possibly endothelium-derived hyperpo-
larizing factor)–mediated endothelium-dependent forearm va-
sodilation in postmenopausal women. In the present study, it is
possible that potentiation of endothelium-dependent vasodila-
tion by estrogen increased the myocardial blood flow and
ameliorated the dobutamine-induced worsening of symptoms,
ECG findings and LV wall motion.
2. The endothelium-independent and calcium antagonistic
vasodilating effects of estrogen may also explain in part its
anti-ischemic effect. As functional estrogen receptor has been
demonstrated on vascular smooth muscle cells in the human
saphenous vein and mammary artery (25), it is highly possible
that this also is the case in the human coronary artery.
3. An antioxidant effect of estrogen might be involved in the
anti-ischemic effect of the hormone. However, this possibility
may be less likely, at least in the present study, because the
levels of lipid peroxides, a marker of systemic production of
oxygen-derived free radicals (26), did not decrease with a low
or a high dose of estrogen.
In the present study, we used conjugated estrogen because
it is the only estrogen agent that can be used for intravenous
administration in our country. As serum levels of both estrone
and estradiol were increased after administration of conju-
gated estrogen in our study, both estrogen fractions may
contribute to the anti-ischemic effect of estrogen. Whereas
comparative vascular effects of estrone and estradiol remain to
be examined, estradiol is three times as potent as estrone in its
anti-oxidant effect (27).
A comparison of the serum levels of estrone and estradiol
(Fig. 1) with the anti-ischemic effects of estrogen (Fig. 2 to 4)
indicates that the logarithmic values of the estrogen levels
appear to correlate with the hormone’s anti-ischemic effects. It
also should be noted that even a low dose of estrogen (1.25 mg
intravenously) that achieved physiologic serum levels of the
hormone exerted anti-ischemic effects in postmenopausal
women with CAD.
Limitations of the study. Several limitations of our study
could be cited. 1) We included only eight patients. However,
the anti-ischemic effects of estrogen were evident even with
this small number. 2) We investigated only the immediate
effects of estrogen. A recent study (28) found that long-term
estrogen replacement therapy that achieved physiologic levels
of estrogen did not improve exercise tolerance by treadmill test
in healthy postmenopausal women. It remains to be examined
Figure 4. Changes in wall motion index score evaluated by echocar-
diography. Data are presented as mean value 6 SEM (n 5 8).
Estrogen (E) dose-dependently ameliorated the wall motion index
score (p , 0.01 by ANOVA).
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whether long-term estrogen replacement therapy increases
exercise tolerance in postmenopausal women with CAD. 3)
We did not store the images in a digitized format or review in
a quad screen format but recorded them on S-VHS tapes. Side
by side cine loop format is generally accepted to be a superior
way for analyzing DSE. However, a recent study (29) suggested
that, although digitized analysis would be more appropriate,
traditional videotape analysis may also be used in DSE. 4) We
included three patients with baseline wall motion abnormali-
ties. However, the beneficial effects of estrogen were noted in
our postmenopausal patients with CAD, regardless of the
presence or absence of baseline wall motion abnormalities.
In summary, we were able to demonstrate that short-term
estrogen administration ameliorates dobutamine-induced
myocardial ischemia. Our finding may have important clinical
implications for understanding both the pathogenesis and the
management of CAD in postmenopausal women.
We thank Chie Fukagawa and Drs. Shin-ichi Ando, Hiroaki Yamamoto and
Jun-ichi Oyama for their kind cooperation in this study.
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